ES2169727T3 - Compuestos heterociclicos de eter que mejoran la funcion cognitiva. - Google Patents

Compuestos heterociclicos de eter que mejoran la funcion cognitiva.

Info

Publication number
ES2169727T3
ES2169727T3 ES93923826T ES93923826T ES2169727T3 ES 2169727 T3 ES2169727 T3 ES 2169727T3 ES 93923826 T ES93923826 T ES 93923826T ES 93923826 T ES93923826 T ES 93923826T ES 2169727 T3 ES2169727 T3 ES 2169727T3
Authority
ES
Spain
Prior art keywords
eter
cognitive function
improve cognitive
compounds
heterociclical
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES93923826T
Other languages
English (en)
Inventor
Melwyn A Abreo
David E Gunn
Nan-Horng Lin
Richard L Elliott
David S Garvey
Suzanne A Lebold
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Abbott Laboratories
Original Assignee
Abbott Laboratories
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Abbott Laboratories filed Critical Abbott Laboratories
Application granted granted Critical
Publication of ES2169727T3 publication Critical patent/ES2169727T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

NUEVOS COMPUESTOS DE ETER HETEROCICLICO DE FORMULA (I) EN LA QUE A, B Y R2 SE DEFINEN ESPECIFICAMENTE, O SALES FARMACEUTICAMENTE ACEPTABLES O PRODROGAS DE ESTOS, QUE SON POTENTES Y SELECTIVOS LIGANDOS EN RECEPTORES DE CANAL COLINERGICO, UTIL EN EL TRATAMIENTO DE TRASTORNOS MENTALES, NEUROLOGICOS Y COGNITIVOS CARACTERIZADOS POR LA FUNCION COLINERGICA REDUCIDA.
ES93923826T 1992-10-09 1993-10-08 Compuestos heterociclicos de eter que mejoran la funcion cognitiva. Expired - Lifetime ES2169727T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US95900592A 1992-10-09 1992-10-09

Publications (1)

Publication Number Publication Date
ES2169727T3 true ES2169727T3 (es) 2002-07-16

Family

ID=25501548

Family Applications (1)

Application Number Title Priority Date Filing Date
ES93923826T Expired - Lifetime ES2169727T3 (es) 1992-10-09 1993-10-08 Compuestos heterociclicos de eter que mejoran la funcion cognitiva.

Country Status (12)

Country Link
EP (1) EP0663912B1 (es)
JP (1) JP3098035B2 (es)
KR (1) KR100311546B1 (es)
AT (1) ATE210656T1 (es)
AU (1) AU687017B2 (es)
CA (1) CA2136075C (es)
DE (1) DE69331329T2 (es)
DK (1) DK0663912T3 (es)
ES (1) ES2169727T3 (es)
IL (1) IL107184A (es)
PT (1) PT663912E (es)
WO (1) WO1994008992A1 (es)

Families Citing this family (76)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5948793A (en) * 1992-10-09 1999-09-07 Abbott Laboratories 3-pyridyloxymethyl heterocyclic ether compounds useful in controlling neurotransmitter release
US5852041A (en) * 1993-04-07 1998-12-22 Sibia Neurosciences, Inc. Substituted pyridines useful as modulators of acethylcholine receptors
US5605908A (en) * 1994-10-24 1997-02-25 Eli Lilly And Company Heterocyclic compounds and their use
US5998404A (en) * 1994-10-24 1999-12-07 Eli Lilly And Company Heterocyclic compounds and their use
US5585388A (en) * 1995-04-07 1996-12-17 Sibia Neurosciences, Inc. Substituted pyridines useful as modulators of acetylcholine receptors
IL118279A (en) * 1995-06-07 2006-10-05 Abbott Lab Compounds 3 - Pyridyloxy (or Thio) Alkyl Heterocyclic Pharmaceutical Compositions Containing Them and Their Uses for Preparing Drugs to Control Synaptic Chemical Transmission
JP2000500452A (ja) * 1995-11-13 2000-01-18 イーライ・リリー・アンド・カンパニー 不安の処置法
US5794887A (en) 1995-11-17 1998-08-18 Komerath; Narayanan M. Stagnation point vortex controller
US6979695B2 (en) 1996-04-23 2005-12-27 Targacept, Inc. Compounds capable of activating cholinergic receptors
US5629325A (en) * 1996-06-06 1997-05-13 Abbott Laboratories 3-pyridyloxymethyl heterocyclic ether compounds useful in controlling chemical synaptic transmission
US6437138B1 (en) 1996-06-06 2002-08-20 Abbott Laboratories 3-pyridyloxymethyl heterocyclic ether compounds useful in controlling chemical synaptic transmission
US6133253A (en) * 1996-12-10 2000-10-17 Abbott Laboratories 3-Pyridyl enantiomers and their use as analgesics
CN1125064C (zh) * 1996-12-10 2003-10-22 艾博特公司 3－吡啶基对映体及其作为镇痛剂的用途
WO1998048801A1 (en) * 1997-04-26 1998-11-05 Sumitomo Pharmaceuticals Co., Ltd. 2-azabicyclo compounds
US6525065B1 (en) 1997-06-30 2003-02-25 Targacept, Inc. Pharmaceutical compositions and methods for effecting dopamine release
US7214686B2 (en) 1997-06-30 2007-05-08 Targacept, Inc. Pharmaceutical compositions and methods for effecting dopamine release
US6624173B1 (en) 1997-06-30 2003-09-23 Targacept, Inc. Pharmaceutical compositions for treating and/or preventing CNS disorders
EP1034174B1 (en) * 1997-11-05 2003-08-13 Neurosearch A/S Azaring-ether derivatives and their use as nicotinic ach receptor modulators
PT1047690E (pt) * 1997-12-19 2004-07-30 Abbott Lab Compostos eter e tioeter heterociclicos uteis no controlo da transmissao quimica sinaptica
BR9907172A (pt) * 1998-04-02 2000-10-10 Reynolds Tobacco Co R Derivados de azatriciclo[3.3.1.1] decano e composições farmacêuticas contendo-os
CA2317572A1 (en) 1998-04-02 1999-10-14 Jared Miller Wagner Pharmaceutical compositions and methods for use
US6218383B1 (en) 1998-08-07 2001-04-17 Targacept, Inc. Pharmaceutical compositions for the prevention and treatment of central nervous system disorders
US6953855B2 (en) 1998-12-11 2005-10-11 Targacept, Inc. 3-substituted-2(arylalkyl)-1-azabicycloalkanes and methods of use thereof
US6432975B1 (en) * 1998-12-11 2002-08-13 Targacept, Inc. Pharmaceutical compositions and methods for use
US20010031771A1 (en) 1999-05-24 2001-10-18 Gary Maurice Dull Pharmaceutical compositions and methods for use
US6544976B1 (en) 1999-07-09 2003-04-08 Ortho-Mcneil Pharmaceutical, Inc. Neurotrophic 2-azetidinecarboxylic acid derivatives, and related compositions and methods
EP1212319A2 (en) * 1999-09-14 2002-06-12 Abbott Laboratories 3-pyrrolidinyloxy-3'-pyridyl ether compounds useful for controlling chemical synaptic transmission
US6890935B2 (en) 1999-11-01 2005-05-10 Targacept, Inc. Pharmaceutical compositions and methods for use
US6812314B2 (en) 2001-10-17 2004-11-02 University Of Florida Thermally responsive polymer materials and uses thereof
JP2005538683A (ja) 2001-12-14 2005-12-22 ターガセプト，インコーポレイテッド 中枢神経系疾患の治療のための方法及び組成物
PT1519939E (pt) 2002-07-05 2010-02-10 Targacept Inc Compostos n-arildiazaspirocíclicos e métodos para a sua preparação e utilização
WO2004009775A2 (en) 2002-07-19 2004-01-29 Targacept, Inc. Methods and compositions relating to chimeric nicotinic receptor subunits
GB0220581D0 (en) 2002-09-04 2002-10-09 Novartis Ag Organic Compound
US7098331B2 (en) 2003-03-05 2006-08-29 Targacept, Inc. Arylvinylazacycloalkane compounds and methods of preparation and use thereof
CA2539811A1 (en) 2003-10-15 2005-04-28 Targacept, Inc. Azabicycyclic compounds for relieving pain and treating central nervous system disorders
US20070191815A1 (en) 2004-09-13 2007-08-16 Chrono Therapeutics, Inc. Biosynchronous transdermal drug delivery
PE20060437A1 (es) 2004-06-18 2006-06-08 Novartis Ag COMPUESTOS AZA-BICICLONONANOS COMO LIGANDOS COLINERGICOS DE nAChR
GB0415746D0 (en) 2004-07-14 2004-08-18 Novartis Ag Organic compounds
AU2005287037A1 (en) 2004-09-20 2006-03-30 Targacept, Inc. Azaspiroalkene and azaspiroalkane compounds with nicotinic cholinergic receptor activity
UA88792C2 (ru) 2004-11-10 2009-11-25 Таргасепт, Інк. Гидроксибензоатные соли метаникотиновых соединений
US7459469B2 (en) 2004-11-10 2008-12-02 Targacept, Inc. Hydroxybenzoate salts of metanicotine compounds
US7732607B2 (en) 2005-08-22 2010-06-08 Anatoly Mazurov Heteroaryl-substituted diazatricycloalkanes and methods of use thereof
GB0521508D0 (en) 2005-10-21 2005-11-30 Novartis Ag Organic compounds
GB0525673D0 (en) 2005-12-16 2006-01-25 Novartis Ag Organic compounds
GB0525672D0 (en) 2005-12-16 2006-01-25 Novartis Ag Organic compounds
EP2021325A2 (en) 2006-05-09 2009-02-11 AstraZeneca AB Salt forms of (2s)-(4e)-n-methyl-5-[3-(5-isopropoxypyridin)yl]-4-penten-2-amine
TWI389889B (zh) 2006-05-09 2013-03-21 Targacept Inc （２ｓ）-（４ｅ）-ｎ-甲基-５-〔３-（５-異丙氧基吡啶）基〕-４-戊烯-２-胺之新穎多晶型
TWI405763B (zh) 2006-11-02 2013-08-21 Targacept Inc 菸鹼乙醯膽鹼受體亞型選擇性之二氮雜雙環烷類醯胺
CN101568258A (zh) * 2006-11-29 2009-10-28 巴斯夫欧洲公司 用于对抗害虫的吡啶衍生物
EP2112923A1 (en) 2007-01-22 2009-11-04 Targacept Inc. Intranasal, buccal, and sublingual administration of metanicotine analogs
TW200845977A (en) 2007-03-30 2008-12-01 Targacept Inc Sub-type selective azabicycloalkane derivatives
EP1977746B8 (en) 2007-04-02 2014-09-24 Parkinson's Institute Methods and compositions for reduction of side effects of therapeutic treatments
SA08290475B1 (ar) 2007-08-02 2013-06-22 Targacept Inc (2s، 3r)-n-(2-((3-بيردينيل)ميثيل)-1-آزا بيسيكلو[2، 2، 2]أوكت-3-يل)بنزو فيوران-2-كربوكساميد، وصور أملاحه الجديدة وطرق استخدامه
DK2217597T3 (da) 2007-10-01 2011-06-20 Comentis Inc Quinuclidin-4-ylmethyl-1h-indol-3-carboxylatderivater som alpha-7-nicotin-acetylcholin-receptor-ligander til behandling af Alzheimers sygdom
AU2009303545A1 (en) * 2008-10-14 2010-04-22 Psychogenics, Inc Nicotinic acetylcholine receptor ligands and the uses thereof
TW201024283A (en) 2008-12-01 2010-07-01 Targacept Inc Synthesis and novel salt forms of (R)-3-((E)-2-(pyrrolidin-3-yl)vinyl)-5-(tetrahydropyran-4-yloxy)pyridine
IL266097B (en) 2008-12-01 2022-07-01 Oyster Point Pharma Inc Mono-orotate acid addition salt of r(–5–)–e(–2–)pyrrolidine––3ylvinyl)pyrimidine
US9145396B2 (en) 2008-12-01 2015-09-29 Targacept, Inc. Synthesis and novel salt forms of (R)-5-((E)-2-pyrrolidin-3ylvinyl)pyrimidine
WO2010080757A2 (en) 2009-01-07 2010-07-15 Astrazeneca Ab Combinations with an alpha-4beta-2 nicotinic agonist
TW201031664A (en) 2009-01-26 2010-09-01 Targacept Inc Preparation and therapeutic applications of (2S,3R)-N-2-((3-pyridinyl)methyl)-1-azabicyclo[2.2.2]oct-3-yl)-3,5-difluorobenzamide
AU2010328419A1 (en) 2009-12-07 2012-06-21 Targacept, Inc. 3,6-diazabicyclo[3.1.1]heptanes as neuronal nicotinic acetylcholine receptor ligands
BR112012029326A2 (pt) 2010-05-20 2017-08-08 Astrazeneca Ab processo para a preparação de animais olefínicas substituídas por arila
RU2582339C2 (ru) 2010-05-27 2016-04-27 Таргасепт, Инк. Неконкурентные антагонисты никотиновых рецепторов
WO2012125518A1 (en) 2011-03-14 2012-09-20 Targacept, Inc. Salt forms of 3 - cyclopropylcarbonyl - 3, 6 - diazabicyclo [3.1.1] heptane
WO2012129262A1 (en) 2011-03-23 2012-09-27 Targacept, Inc. Treatment of attention deficit/hyperactivity disease
TW201311698A (zh) 2011-08-22 2013-03-16 Targacept Inc 作為神經元菸鹼乙醯膽鹼受體配位體之１，４－二氮雜雙環［３．２．２］壬烷
EP2776030B1 (en) * 2011-11-11 2020-05-13 Georgetown University 2,5-disubstituted-pyridyl nicotinic ligands, and methods of use thereof
US10105487B2 (en) 2013-01-24 2018-10-23 Chrono Therapeutics Inc. Optimized bio-synchronous bioactive agent delivery system
TW201617342A (zh) 2014-07-11 2016-05-16 阿法馬根公司 調節α７活性之啶類
JP2018511355A (ja) 2015-01-28 2018-04-26 クロノ セラピューティクス インコーポレイテッドＣｈｒｏｎｏ Ｔｈｅｒａｐｅｕｔｉｃｓ Ｉｎｃ． 薬剤送達方法及びシステム
US9724340B2 (en) 2015-07-31 2017-08-08 Attenua, Inc. Antitussive compositions and methods
CN105418477B (zh) * 2015-12-22 2018-12-21 爱斯特（成都）生物制药股份有限公司 降低雷迪帕韦中间体中非对映异构体杂质含量的方法
WO2018129304A1 (en) 2017-01-06 2018-07-12 Chrono Therapeutics Inc. Transdermal drug delivery devices and methods
AU2019279884B2 (en) 2018-05-29 2025-01-30 Morningside Venture Investments Limited Drug delivery methods and systems
JP2022507660A (ja) 2018-11-16 2022-01-18 モーニングサイド ベンチャー インベストメンツ リミテッド 温度によって調節される経皮薬剤送達システム
US20230225323A1 (en) * 2020-06-24 2023-07-20 Philip Morris Products S.A. Compositions and methods for parasite control

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA848275B (en) * 1983-12-28 1985-08-28 Degussa New piridine-2-ethers or pyridine-2-thioethers having a nitrogen-containing cycloaliphatic ring
CA1307790C (en) * 1987-08-04 1992-09-22 Ian Anthony Cliffe Ethers
YU84791A (sh) * 1990-05-19 1994-06-10 Boehringer Ingelheim Kg. Biciklicni 1-aza-cikloalkalni

Also Published As

Publication number Publication date
CA2136075A1 (en) 1994-04-28
EP0663912A4 (en) 1995-02-17
JPH08502481A (ja) 1996-03-19
IL107184A0 (en) 1994-01-25
PT663912E (pt) 2002-06-28
JP3098035B2 (ja) 2000-10-10
WO1994008992A1 (en) 1994-04-28
KR950701920A (ko) 1995-05-17
AU687017B2 (en) 1998-02-19
DK0663912T3 (da) 2002-04-15
IL107184A (en) 1997-08-14
EP0663912A1 (en) 1995-07-26
DE69331329D1 (de) 2002-01-24
ATE210656T1 (de) 2001-12-15
DE69331329T2 (de) 2002-08-08
EP0663912B1 (en) 2001-12-12
AU5355794A (en) 1994-05-09
KR100311546B1 (ko) 2005-12-06
CA2136075C (en) 2004-12-14

Similar Documents

Publication Publication Date Title
PT663912E (pt) Compostos de eter heterociclico que aumentam a funcao cognitiva
ATE273296T1 (de) 3-pyridyloxymethyl heterocyclische ether verbindungen für die kontrolle chemischer synaptischer übertragung
FI931202A0 (fi) Antifungala cykliska peptider och foerfarande foer framstaellning av dessa
MY117896A (en) Quinazoline derivatives
NL1002835A1 (nl) Synergistisch stabilisatormengsel.
FI931888A0 (fi) Kramploesande cykliska fruktopyranossulfiter -och sulfater
FI914723A0 (fi) 17b-substituerade 4-aza-5a-androstan -3-jon-derivat och foerfarande foer framstaellning av desamma.
MX9300222A (es) Nuevos derivados de arilcicloalquilo, su preparacion y su utilizacion.
DE69505470D1 (de) Pyrrolocarbazol
ES2136887T3 (es) Derivados antifungicos de sordaridina.
SE9100920D0 (sv) New active compounds
FI962976L (fi) Viherkaihin hoitoon tarkoitettuja koostumuksia, jotka sisältävät beta-salpaajaa
ES500334A0 (es) Procedimiento para la obtencion de 1,1-difenil-2-(1,2,4-tri-azol-1-il)-etan-1-oles
ATE156486T1 (de) Fungizide 3,4-diaryl-(5h)-furan-2-onederivate
ATE38519T1 (de) Azahomoerythromycin-b-derivate und zwischenprodukte.
DK0623131T3 (da) Alkylderivater af trazodon med CNS-aktivitet
PT1049672E (pt) Derivados de azetidinocarboxamida para o tratamento de disturbios do snc
DE69108794D1 (de) Klärungsmittel für Polyolefine und Polyolefine, die diese enthalten.
PT1049670E (pt) Derivados de azetidinocarboxamida para o tratamento de perturbacoes do snc
MA20461A1 (fr) Procede de preparation de nouveaux derives de l'isoxazoloquinoleine
SE8700566L (sv) Tetracykliska kinazolinoner
ATE176242T1 (de) Uck14-verbindungen
FR2356647A1 (fr) Derives 3-aldehyde et 3-acetals de la 6,11-dihydro-dibenzo(b.e.)-thiepinne-11-one et procedes d'obtention
FI933928A0 (fi) Heteroarenylpiperaziner, foerfarande foer framstaellning av dessa och anvaendning som laekemedel
FR2453134A1 (fr) Derives d'anilinotropone et leur utilisation pour leurs activites anti-inflammatoire et analgesique

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 663912

Country of ref document: ES